CRX with neutralizing properties constitutes the 3 rd cornerstone of Bionor’s HIV program

Oslo, February 7, 2019 The recent Proof of Mechanism shown for CRX demonstrates the dynamic properties of this product obstructing both of the well-known virus entry mechanisms CCR5 and CXCR4 in a way that prevents the virus from evading the blockage through escape mutations. The product CRX constitutes the 3rd of the three cornerstones of …

Read more

Bionor’s 3rd vaccine candidate, CRX, Proof of Mechanism established

Oslo, January 23, 2019. Bionor is pleased to announce that Proof of Mechanism is established for our 3rd vaccine candidate, CRX. This product aims to prevent binding between gp120 V3 loop and CCR5/CXCR4 coreceptors and facilitate virus neutralization. Lead optimization and drug characterization with Proof of Principle will be established within the next 6 – …

Read more

Bionor has acquired its 3rd HIV vaccine candidate, CRX.

Oslo, January 10, 2019 The acquisition is in the form of an exchange of patents and rights between Bionor and Immunor AS. During Bionor’s equity raise in December 2017, Bionor pledged to dispose of all its non-HIV activities. These activities have now been transferred to Immunor through a mutual assignment agreement where Immunor acquires all …

Read more

Change of name to Bionor Holding AS

Oslo, January 29.1.2018 In an Extraordinary General Meeting today, the shareholders unanimously adopted to change the name of the company from Bionor Pharma AS to Bionor Holding AS.  The change of name to Bionor Holding AS aligns the name with the operational activities of the Bionor group.

Birger Sørensen and his team closed the purchase and funding of Bionor today

Oslo, December 8, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017 with financial closing as of today. With the assistance of Norse Securities, the new owners/management have successfully raised funds for the purchase and future operations. Birger Sørensen and his team will immediately start …

Read more

Strategic partnership between Smerud Medical Research International and Bionor

Oslo, November 24, 2017 Bionor is proud to announce that the company on November 24 entered into a strategic partnership with Smerud Medical Research International (SMRI). This partnership will focus on the clinical and regulatory development program towards a marketing approval and will also cover other development aspects such as financing and commercialization.

New strategy for combining Vacc-4x and Vacc-C5 with a defined path that can lead to a regulatory approval and commercialization

Bionor’s strategy is to develop the combination of its two proprietary therapeutic HIV vaccines Vacc-4x and Vacc-C5 and seek advice on and adapt its regulatory path so that a marketing approval for a functional cure for HIV can be achieved. As part of this strategy, Bionor will extend and complete the Vacc-C5 dose escalation studies …

Read more

The founder of Bionor, Birger Sørensen, and his team has repurchased the company

Oslo, September 28, 2017 Bionor was purchased by the founder of Bionor AS, Birger Sørensen and his team, on September 28, 2017. The new owners/management will focus on implementing a new strategy that includes the final development of the combined vaccines that provides a functional cure against HIV, defining the regulatory path and seeking a …

Read more

Vacc-C5 phase I/II clinical study published in BMC infectious diseases

The Vacc-C5 clinical trial is included as part of the doctor thesis of Kristin Brekke at Oslo University Hospital Background Levels of non-neutralising antibodies (AB) to the C5 domain of HIV Env gp120 are inversely related to progression of HIV infection. In this phase I/II clinical study we investigated safety of Vacc-C5, a peptide-based therapeutic …

Read more

Bionor Pharma presents REDUC clinical trial results as a poster at GLOBVAC

The Research Council of Norway’s 10th Conference on Global Health and Vaccination Research where Bionor presents the Vacc-4x REDUC clinical trial results. The REDUC clinical trial was partly funded by a GLOBVAC grant.
1236 Next